Skip to main content
SpringerLink
Log in

Renal Cancer Molecular Therapy

  • Living reference work entry
  • First Online:
Encyclopedia of Cancer

  • 32 Accesses

Synonyms

Renal cancer pharmacologic therapy

Definition

Renal cancer (synonym: renal carcinoma, kidney cancer) molecular therapy refers to the use of novel medications to specifically target molecular processes leading to, or associated with, renal cancer. These novel medications include bevacizumab, an antibody to the vascular endothelial growth factor (VEGF) and the small molecules, sunitinib, sorafenib, and temsirolimus or its equivalent everolimus, all inhibiting phosphorylating enzymes (kinase) critical to the growth of renal tumors.

Characteristics

Introduction

Renal cell carcinoma (RCC) affects three in 10,000 people and accounts for 2.3 % of cancer deaths in the USA. The median age at diagnosis is 66 years and the median age of RCC-associated death is 70. The most common types of RCC are defined by their histopathologypattern, i.e., clear-cell RCC and papillary RCC, accounting for 75 % and 12 % of all RCC, respectively. The clear-cell RCC morphology usually derives from an...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Clark PE (2007) Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol 17:331–336

    Article  PubMed  Google Scholar 

  • Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. New Engl J Med 353:2477–2490

    Article  CAS  PubMed  Google Scholar 

  • Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med 356:2271–2281

    Article  CAS  PubMed  Google Scholar 

  • Larkin JMG, Chowdhury S, Gore ME (2007) Drug insight: advances in renal cell carcinoma and the role of targeted therapies. Nat Clin Pract Oncol 4:470–479

    Article  CAS  PubMed  Google Scholar 

  • Rathmell WK, Martz CA, Rini BI (2007) Renal cell carcinoma. Curr Opin Oncol 19:234–240

    Article  PubMed  Google Scholar 

  • Turcotte T, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ (2008) A molecule targeting VHL-deficient renal cell carcinoma that Induces autophagy. Cancer Cell 14(1):90–102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

See Also

  • (2012) AKT. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 115. doi:10.1007/978-3-642-16483-5_163

    Google Scholar 

  • (2012) Allelic Loss. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 137. doi:10.1007/978-3-642-16483-5_186

    Google Scholar 

  • (2012) Cell Cycle. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 737. doi:10.1007/978-3-642-16483-5_994

    Google Scholar 

  • (2012) Computed Tomography. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 964–965. doi:10.1007/978-3-642-16483-5_1295

    Google Scholar 

  • (2012) Endothelial Cells. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1251. doi:10.1007/978-3-642-16483-5_1896

    Google Scholar 

  • (2012) Interleukin-2. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1892. doi:10.1007/978-3-642-16483-5_3097

    Google Scholar 

  • (2012) Kinase. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1943. doi:10.1007/978-3-642-16483-5_3217

    Google Scholar 

  • (2012) KIT. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 1945–1946. doi:10.1007/978-3-642-16483-5_3228

    Google Scholar 

  • (2012) Lysosome. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2128. doi:10.1007/978-3-642-16483-5_3472

    Google Scholar 

  • (2012) Monoclonal Antibody Therapy. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 2367–2368. doi:10.1007/978-3-642-16483-5_3823

    Google Scholar 

  • (2012) MTOR. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2384. doi:10.1007/978-3-642-16483-5_3867

    Google Scholar 

  • (2012) Multidrug Resistance Proteins. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2393. doi:10.1007/978-3-642-16483-5_3888

    Google Scholar 

  • (2012) Pericyte. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 2814–2815. doi:10.1007/978-3-642-16483-5_4448

    Google Scholar 

  • (2012) Posttranslational Modification. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2966. doi:10.1007/978-3-642-16483-5_4696

    Google Scholar 

  • (2012) Radiation Therapy. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3144. doi:10.1007/978-3-642-16483-5_4907

    Google Scholar 

  • (2012) Radiofrequency Ablation. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3148. doi:10.1007/978-3-642-16483-5_6490

    Google Scholar 

  • (2012) Renal Cancer. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 3225–3226. doi:10.1007/978-3-642-16483-5_6575

    Google Scholar 

  • (2012) Resistance. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3263. doi:10.1007/978-3-642-16483-5_5052

    Google Scholar 

  • (2012) Sunitinib. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3562. doi:10.1007/978-3-642-16483-5_5575

    Google Scholar 

  • (2012) Transforming Growth Factor Alpha. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3758. doi:10.1007/978-3-642-16483-5_5915

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Hadassah-Hebrew University Medical Center, Department of Medicine, Jerusalem, Israel

    Yosef S. Haviv

Authors
  1. Yosef S. Haviv
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yosef S. Haviv .

Editor information

Editors and Affiliations

  1. Abt. Tumorgenetik, Deutsches Krebsforschungszentrum, Heidelberg, Germany

    Manfred Schwab

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Haviv, Y.S. (2015). Renal Cancer Molecular Therapy. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_6330-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-27841-9_6330-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Online ISBN: 978-3-642-27841-9

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation